ADMA Biologics Inc (NASDAQ:ADMA) – Equities researchers at Jefferies Financial Group boosted their FY2023 earnings per share estimates for ADMA Biologics in a research report issued to clients and investors on Wednesday, November 6th. Jefferies Financial Group analyst A. Petrone now forecasts that the biotechnology company will earn $1.50 per share for the year, up from their prior estimate of $1.48.
ADMA Biologics (NASDAQ:ADMA) last posted its quarterly earnings results on Wednesday, November 6th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.23) by $0.04. ADMA Biologics had a negative net margin of 323.54% and a negative return on equity of 214.26%. The company had revenue of $7.22 million during the quarter, compared to the consensus estimate of $5.71 million.
ADMA has been the subject of a number of other reports. BidaskClub upgraded shares of ADMA Biologics from a “hold” rating to a “buy” rating in a research report on Wednesday. Dawson James downgraded shares of ADMA Biologics from a “buy” rating to a “neutral” rating and set a $4.00 price target for the company. in a research report on Monday, August 12th. ValuEngine upgraded shares of ADMA Biologics from a “hold” rating to a “buy” rating in a research report on Friday, September 20th. Finally, Maxim Group set a $12.00 price target on shares of ADMA Biologics and gave the company a “buy” rating in a research report on Monday, October 21st. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $10.20.
Shares of ADMA stock traded down $0.21 during midday trading on Friday, reaching $4.31. 940,100 shares of the company traded hands, compared to its average volume of 884,660. The firm’s 50 day simple moving average is $4.59 and its two-hundred day simple moving average is $4.26. ADMA Biologics has a 1-year low of $2.08 and a 1-year high of $6.31. The company has a debt-to-equity ratio of 1.79, a current ratio of 10.26 and a quick ratio of 7.93. The firm has a market cap of $304.89 million, a PE ratio of -2.97 and a beta of 2.70.
Several institutional investors and hedge funds have recently modified their holdings of the company. Private Advisors LLC purchased a new position in shares of ADMA Biologics during the 2nd quarter worth approximately $41,000. Citadel Advisors LLC increased its stake in shares of ADMA Biologics by 96.3% during the 2nd quarter. Citadel Advisors LLC now owns 22,187 shares of the biotechnology company’s stock worth $86,000 after purchasing an additional 10,887 shares in the last quarter. Jane Street Group LLC increased its stake in shares of ADMA Biologics by 25.1% during the 2nd quarter. Jane Street Group LLC now owns 58,374 shares of the biotechnology company’s stock worth $226,000 after purchasing an additional 11,711 shares in the last quarter. Parametric Portfolio Associates LLC purchased a new position in shares of ADMA Biologics during the 2nd quarter worth approximately $49,000. Finally, Tower Research Capital LLC TRC increased its stake in shares of ADMA Biologics by 13,268.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 13,368 shares of the biotechnology company’s stock worth $52,000 after purchasing an additional 13,268 shares in the last quarter. 59.10% of the stock is owned by institutional investors and hedge funds.
About ADMA Biologics
ADMA Biologics, Inc, a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease.
Featured Story: What is the outlook for the FAANG stocks?
Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.